Portal:CPTAC/Hallmark/Therapeutics
From WikiPathways
(Difference between revisions)
| Line 12: | Line 12: | ||
*[[Pathway:WP4585]] Cancer immunotherapy by PD-1 blockade | *[[Pathway:WP4585]] Cancer immunotherapy by PD-1 blockade | ||
*[[Pathway:WP4582]] Cancer immunotherapy by CTLA4 blockade | *[[Pathway:WP4582]] Cancer immunotherapy by CTLA4 blockade | ||
| + | *[[Pathway:WP4559]] Interactions between immune cells and microRNAs in tumor microenvironment | ||
Revision as of 17:51, 10 October 2019
- Pathway:WP3672 LncRNA-mediated mechanisms of therapeutic resistance
- Pathway:WP3640 Imatinib and Chronic Myeloid Leukemia
- Pathway:WP3614 Photodynamic therapy-induced HIF-1 survival signaling
- Pathway:WP3617 Photodynamic therapy-induced NF-kB survival signaling
- Pathway:WP3879 4-hydroxytamoxifen, Dexamethasone, and Retinoic Acids Regulation of p27 Expression
- Pathway:WP1601 Fluoropyrimidine Activity
- Pathway:WP3 Phytochemical activity on NRF2 transcriptional activation
- Pathway:WP4357 NRF2-ARE regulation
- Pathway:WP4301 Inhibition of exosome biogenesis and secretion by Manumycin A in CRPC cells
- Pathway:WP3844 PI3K-AKT-mTOR signaling pathway and therapeutic opportunities
- Pathway:WP3593 MicroRNA for Targeting Cancer Growth and Vascularization in Glioblastoma
- Pathway:WP4585 Cancer immunotherapy by PD-1 blockade
- Pathway:WP4582 Cancer immunotherapy by CTLA4 blockade
- Pathway:WP4559 Interactions between immune cells and microRNAs in tumor microenvironment
